Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 211 to 220 of 1106 total matches.

Oral Semaglutide (Rybelsus) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019  (Issue 1583)
-cell tumors (based on animal data; no corroborating human data); the drug is contraindicated ...
An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation (Ozempic) since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):166-8 |  Show IntroductionHide Introduction

Clascoterone Cream (Winlevi) for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
. PREGNANCY AND LACTATION — There are no data on the use of clascoterone 1% cream in pregnant women ...
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the FDA.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):202-4 |  Show IntroductionHide Introduction

Drugs for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020  (Issue 1600)
, and reverse causation could have affected the results.9 Pregnancy and Lactation – Data on the use of topical ...
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96 |  Show IntroductionHide Introduction

In Brief: Clopidogrel and Omeprazole

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2010  (Issue 1352)
should also take a PPI, but not omeprazole. Until more data become available on other PPIs ...
Use of a proton pump inhibitor (PPI) to protect against gastrointestinal (GI) bleeding in patients taking the antiplatelet agent clopidogrel (Plavix) may interfere with the activation of clopidogrel and diminish its antiplatelet effect, increasing the risk of cardiovascular events.1 A randomized, placebo-controlled trial (COGENT) has found that use of the PPI omeprazole in patients taking clopidogrel in addition to aspirin decreased the incidence of GI bleeding without increasing the risk of a cardiovascular event, but the number of cardiovascular events was small and the formulation of...
Med Lett Drugs Ther. 2010 Nov 29;52(1352):93 |  Show IntroductionHide Introduction

Elderberry for Influenza

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
. PREGNANCY AND LACTATION — No data are available on the safety of elderberry use during pregnancy or while ...
Patients may ask about taking elderberry for prevention and treatment of influenza. Products containing elderberry are promoted for relief of cold and flu symptoms and as an immune system booster.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):32 |  Show IntroductionHide Introduction

Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
— No data are available to evaluate the efficacy of glycopyrrolate as an adjunct to a proton pump ...
The FDA has approved adjunctive treatment with Dartisla ODT (Edenbridge), a new orally disintegrating tablet (ODT) formulation of the anticholinergic drug glycopyrrolate, to reduce symptoms of a peptic ulcer. Glycopyrrolate oral tablets (Robinul, Robinul Forte, and generics) were approved for the same indication in 1961.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):24 |  Show IntroductionHide Introduction

Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
▪ No data in patients with severe influenza ▪ Not recommended for use in severely immunocompromised ...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e1-5   doi:10.58347/tml.2024.1717d |  Show IntroductionHide Introduction

In Brief: Label Changes for Testosterone Products

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025  (Issue 1726)
has required changes in the labels of all testosterone products to reflect new data on their cardiovascular ...
The FDA has required changes in the labels of all testosterone products to reflect new data on their cardiovascular effects. The updated labels will no longer include a boxed warning about an increased risk of adverse cardiovascular outcomes, but will contain a new warning about an increase in blood pressure.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):62-3   doi:10.58347/tml.2025.1726d |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
≥30.7 The FDA has proposed a maximum labeled SPF value of 60+ because data showing that sunscreen ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction

Zaleplon for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Oct 08, 1999  (Issue 1063)
with the lowest recommended dose according to wholesale price (AWP) listings in First DataBank NDDF, August 20 ...
Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.
Med Lett Drugs Ther. 1999 Oct 8;41(1063):93-4 |  Show IntroductionHide Introduction